Dublin, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
This report provides an extensive analysis of key trends, applications, and technologies shaping the industry from 2023 to 2027. This publication includes expert insights on various facets of the market, including expected growth for newborn Whole Genome Sequencing, advances in Direct to Consumer Testing, and the competitive landscape for sequencing technology.
The detailed report delves into the application of Whole Genome and Exome Sequencing across diverse organisms and products, incorporating an in-depth Direct to Consumer Analysis. With the costs of sequencing technologies decreasing significantly, the industry is observing a surge in investments and the emergence of new market entrants, reminiscent of the early days of the internet era.
Insights from the report highlight:
- The potential for standardizing Whole Genome Sequencing for newborns and its adoption rate across health systems.
- The trajectory and pace of the Direct to Consumer Testing market, including consumer demand and regulatory landscapes.
- Analysis of leading sequencing technologies and their roles in current and future market dynamics.
- The critical barriers facing the industry and actionable insights into overcoming these challenges.
- An extensive global overview, featuring over 800 locations equipped with high throughput sequencing devices.
In addition, the publication offers lucid explanations of technical terminologies and an exploration of niche sectors, including Tumor Cell Sequencing and Gene Expression, that are transforming the landscape. An extensive breakdown is featured, covering detailed forecasts for 14 countries and 5 regions, equipping stakeholders with the knowledge to make informed decisions.
The sector's potential growth and market size estimates for the next five years are meticulously outlined, providing a strategic edge for those looking to invest and engage with the market. This report serves as a foundational resource for understanding the complex environment of Whole Genome and Exome Sequencing markets and capitalizing on the emerging opportunities therein.
Prospective investors, healthcare professionals, and industry analysts will find this report invaluable for navigating the evolving landscape of genomics and making data-driven decisions based on the most recent market research.
Uncovering the Future of Genomic Science
As the domains of genomics and personalized medicine continue to intersect and expand, the insights from this comprehensive research are poised to drive innovation and market growth. The convergence of technology and healthcare has opened a plethora of opportunities for advancements in diagnosis, treatment, and preventive care through Whole Genome and Exome Sequencing.
The insights provided in this research publication build a narrative of success, guiding stakeholders through the advancements and complexities of the rapidly growing Whole Genome and Exome Sequencing markets.
Companies Mentioned
- 10x Genomics, Inc
- 1928 Diagnostics
- 23andME Inc
- Abbott Laboratories
- AccuraGen Inc
- Adaptive Biotechnologies
- Admera Health, LLC
- Agilent/Dako
- Akonni Biosystems
- Amoy Diagnostics Co., Ltd
- Ancestry.com LLC
- Anchor Dx
- ARUP Laboratories
- BaseClear
- Baylor Miraca Genetics Laboratories
- Beckman Coulter Diagnostics
- Becton, Dickinson and Company
- BGI Genomics Co. Ltd
- Bioarray Genetics
- Biocept, Inc.
- Biodesix Inc.
- BioFluidica
- BioGenex
- Biolidics Ltd
- bioMérieux Diagnostics
- Bioneer Corporation
- Bio-Rad Laboratories, Inc
- Bio-Techne
- C2i Genomics
- Caris Molecular Diagnostics
- CellMax Life
- Centogene
- Circulogene
- Clear Labs
- Clinical Genomics
- Complete Genomics, Inc. - A BGI Company
- CosmosID
- Dante Labs
- Datar Cancer Genetics Limited
- Day Zero Diagnostics.
- Diasorin S.p.A.
- Element Biosciences
- Element Biosciences
- Epic Sciences
- Epigenomics AG.
- Eurofins Scientific
- Excellerate Bioscience
- Fabric Genomics
- Freenome
- FUJIFILM Wako Diagnostics
- Fulgent Genetics
- GE Global Research
- Gencove
- Genedrive
- GeneFirst Ltd.
- Genetron Holdings
- Genewiz
- Genomics England
- Genomics Personalized Health (GPH)
- GenomOncology
- Genzyme Corporation
- Grifols
- Guardant Health
- Guardiome
- HeiScreen
- Helix
- Helix OpCo
- Helomics
- Hologic
- HTG Molecular Diagnostics
- Human Longevity, Inc.
- iCellate
- Illumina
- Incell Dx
- Inivata
- Invitae Corporation
- Invivoscribe
- Karius
- Lunglife AI Inc
- Macrogen
- MDNA Life SCIENCES, Inc.
- MDx Health
- Medgenome
- Meridian Bioscience
- Mesa Biotech (Thermo Fisher)
- Mesa Laboratories, Inc.
- miR Scientific
- MNG Labs
- NantHealth, Inc.
- Natera
- Nebula Genomics
- NeoGenomics
- New England Biolabs, Inc.
- Novogene Bioinformatics Technology Co., Ltd.
- Omega Bioservices
- Oncocyte
- OncoDNA
- OpGen
- ORIG3N, Inc.
- Origene Technologies
- Oxford Nanopore Technologies
- Pacific Biosciences
- Panagene
- Pathogenomix
- PathoQuest S.A.
- Personal Genome Diagnostics
- Personalis.
- Precipio
- PrecisionMed
- Promega
- Protagen Diagnostics
- Qiagen
- QuantuMDx
- Regeneron Pharmaceuticals
- Revvity
- Roche Molecular Diagnostics
- Roswell Biotechnologies
- Seegene
- Sequencing.com
- Siemens Healthineers
- simfo GmbH
- Singlera Genomics Inc.
- Singular Genomics
- SkylineDx
- Standard BioTools
- Sure Genomics, Inc.
- Sysmex
- Sysmex Inostics
- Tempus Labs, Inc.
- Thermo Fisher Scientific Inc.
- Ultima Genomics
- Ultima Genomics
- Variantyx
- Volition
- Vyant Bio
- Zymo Research Corp
For more information about this report visit https://www.researchandmarkets.com/r/yzebl5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
